The Nurse Practitioner

July 2005, Volume 30 Number 7 , p 58 - 59 [FREE]


  • Nancy Risser MN, RN, C, ANP
  • Mary Murphy CPNP, PhD, Literature Review Editors


function openWeblink(url,target,width) { if (!width) width = '100%'; var newWindow; newWindow =,target,'width='+width+',height=480,status,resizable,titlebar,toolbar,scrollbars'); newWindow.focus(); } function set_JnlFullText_Print() { metaTag = document.createElement('meta'); metaTag.setAttribute('name','OvidPageId'); metaTag.setAttribute('content','JnlFullText_Print'); head = document.getElementsByTagName('head')[0]; head.appendChild(metaTag); return; } if (window.addEventListener) { // DOM Level 2 Event Module (NS 6+) window.addEventListener('onload',set_JnlFullText_Print(),false); } else if (window.attachEvent) { // IE 5+ Event Model window.attachEvent('onload',set_JnlFullText_Print); } // For anything else, just don't add the event Full Text   #header-block { display: none; } © 2005 Lippincott Williams & Wilkins, Inc. Volume 30(7), July 2005, pp 58-59 Zetia and Rhabdomyolysis [Departments: Literature Review: DRUG INFORMATION]

Section ...


Rhabdomyolysis with Ezetimibe. The Medical Letter 2005;47(1203):17.

FIGURE. No caption a... - Click to enlarge in new windowFIGURE. No caption available.
FIGURE. No caption a... - Click to enlarge in new windowFIGURE. No caption available.

The Canadian equivalent of the Food and Drug Administration has issued a warning about postmarketing reports of myalgia, rhabdomyolysis, hepatitis, pancreatitis, and thrombocytopenia detected in patients who were taking ezetimibe (Zetia). Ezetimibe is used alone or, in the United States, is marketed in a combination with simvastatin (Vytorin). There have been previous case reports of myalgia that have occurred when ezetimibe was added to a previously tolerated statin. These new Canadian reports should alert patients and clinicians that rhabdomyolysis is a potential risk associated with the use of ezetimibe even though it was not detected in initial trials.